个人化医疗的AI的机会

本报告探讨了人工智慧在个人化医疗中的机遇，并深入分析了人工智慧技术如何降低药物研发风险、增强患者分层并促进个人化医疗。报告也介绍了人工智慧在个人化医疗中的实际应用案例和经验教训。

主要内容

• 1. 人工智慧对个人化医疗发展的影响
• 2. 人工智慧技术如何降低药物研发和个人化医疗的风险
• 3. 利用人工智慧来增强人类在标靶辨识和个人化医疗研发方面的能力所面临的关键课题
• 4. 人工智慧如何应用于改善个人化医疗以及从中汲取的经验教训
• 5. 利用人工智慧增强精准医疗市场准入和报销的关键趋势和未来机会
• 6. 生物製药公司如何克服数据障碍，将人工智慧有效地融入个人化医疗计划

主要企业

This report explores the transformative role of artificial intelligence in personalised medicine, focusing on its application in drug discovery and clinical decision making. It provides an in-depth analysis of how AI-enabled technologies are mitigating risks in drug development, enhancing patient stratification and facilitating the personalisation of care. The report also highlights real-world use cases and lessons learned from deploying AI to personalise medical care, offering a comprehensive overview for biopharma professionals looking to navigate the evolving landscape of AI-driven healthcare solutions.

Gain insights into the significant impact of AI on the development of personalised therapies, the key challenges in integrating AI with human capabilities and the future opportunities for biopharma to leverage AI in improving market access and reimbursement strategies.

Key Questions Answered:

• 1. How has AI significantly impacted the development of personalised medicines?
• 2. In what ways have AI-enabled technologies mitigated risks in drug development and personalisation?
• 3. What are the key challenges in utilising AI to enhance human capabilities in target identification and personalised medicine development?
• 4. How has AI been deployed to improve the personalisation of care, and what lessons have been learned?
• 5. What are the key trends and future opportunities for leveraging AI to enhance market access and reimbursement of precision medicine?
• 6. How can biopharma companies overcome data hurdles to effectively integrate AI in personalised medicine initiatives?

Key Companies:

Partial List of Participating Experts:

• Director of AI Capability, AstraZeneca, Spain (own personal views)
• CEO, Insilico Medicine, US
• Digital, Strategy and Innovation Director, The Stem, US
• Vice Chairman and founding CEO, ConcertAI, US
• former Head of UK/EU Clinical Research at Spectral MD, UK
• CEO, LucidQuest, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.